HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardioprotective action of the new stable epoprostenol analogue CG 4203 in rat models of cardiac hypoxia and ischemia.

Abstract
[(5Z,13E,9 alpha,11 alpha,15S)-2,3,4-Trinor - 1,5 - inter-m - phenylene - 6,9 - epoxy - 11,5 - dihydroxy - 15 - cyclohexyl - 16,17,18,19,20-pentanor]- prosta-5,13-dienoic acid (sodium salt) (CG 4203) is a new stable epoprostenol (prostacyclin) analogue with a relative platelet antiaggregatory potency of 0.46 (ADP aggregation in vitro) and a hypotensive potency of 0.14 (anaesthetized rat i.v.) as compared to epoprostenol. In isolated perfused rat hearts, CG 4203 (4.64 X 10(-9) mol/l) significantly attenuated arrhythmias and loss of left ventricular creatine kinase (CK) activity observed in control hearts after 30 min perfusion with hypoxic and 30 min reperfusion with oxygenated Krebs-Ringer solution. In anaesthetized rats, CG 4203 (1.0 microgram X kg-1 X min-1 i.v.) significantly reduced incidence of ventricular fibrillation and increase in plasma CK activity after ligation of the left coronary artery. Infusion of 1.0 and 2.15 micrograms X kg-1 X min-1 CG 4203 i.v. in anaesthetized rats dose-dependently inhibited electrocardiographic changes, i.e. ST depression observed after i.v. injection of 1.0 IU X kg-1 vasopressin. In rat models of sustained myocardial hypoxia, myocardial infarction, and transient cardiac ischemia, CG 4203 thus exerts cardioprotective effects which, depending on the model considered, may be ascribed to either its vasodilatory, coronary dilatory, antiaggregatory or epoprostenol-like cytoprotective activity.
AuthorsB Müller, J Schneider, H H Hennies, L Flohé
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 34 Issue 11 Pg. 1506-9 ( 1984) ISSN: 0004-4172 [Print] Germany
PMID6441579 (Publication Type: Journal Article)
Chemical References
  • Cardiovascular Agents
  • Vasopressins
  • taprostene
  • Epoprostenol
  • Creatine Kinase
  • Nitroglycerin
  • Oxygen
Topics
  • Animals
  • Cardiovascular Agents (pharmacology)
  • Coronary Disease (enzymology, prevention & control)
  • Creatine Kinase (metabolism)
  • Epoprostenol (pharmacology)
  • In Vitro Techniques
  • Male
  • Myocardial Contraction (drug effects)
  • Nitroglycerin (pharmacology)
  • Oxygen (pharmacology)
  • Perfusion
  • Rats
  • Rats, Inbred Strains
  • Vasopressins (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: